Symbols

HELX

Franklin Genomic Advancements ETF·CBOE

--(--)

Key Stats

Assets Under Management

22.25MUSD

Fund Flows (1Y)

4.35MUSD

Dividend Yield

Discount/Premium to NAV

0.03%

Shares Outstanding

600.00K

Expense Ratio

0.50%

About Franklin Genomic Advancements ETF

Issuer

Franklin Advisers, Inc.

Brand

Franklin

Home Page

https://www.franklintempleton.com/investor/investments-and-solutions/investment-options/etfs/overview/29097/franklin-genomic-advancements-etf

Inception Date

Feb 25, 2020

Structure

Open-Ended Fund

Index Tracked

Management Style

Active

Dividend Treatment

Distributes

Distribution Tax Treatment

Qualified dividends

Income Tax Type

Capital Gains

Max ST Capital Gains Rate

39.60%

Max LT Capital Gains Rate

20.00%

Primary Advisor

Franklin Advisers, Inc.

Distributor

Franklin Distributors LLC

HELX invests in global companies benefitting from the advancements of genomic-based research techniques and technologies that are designed to extend or enhance the quality of life. The fund advisor uses fundamental research to identify and select stocks they feel best positioned to capitalize on such genomic advancements. Companies may include those that research, develop, produce or manufacture bionic devices, molecular medicine, pharmaceuticals and agricultural applications. HELX is one of the first three thematic funds to launch from Franklin Templeton.